Hemagen Diagnostics, Inc. is a biotechnology company. The company is headquartered in Columbia, Maryland and currently employs 15 full-time employees. The firm is primarily focused on Veterinary Clinical Diagnostics. The company is also focused on VIRGO, its Human Clinical Diagnostic line of autoimmune and infectious disease products. The firm develops, manufactures and markets a range of test kits used to aid in the diagnosis of certain autoimmune and infectious diseases. The Company’s autoimmune product portfolio includes Hemagen DNA Kit, Hemagen Rheumatoid Factor Kit, VIRGO AMA IgG, VIRGO ANA/Hep-2 IgG, VIRGO Anti-nDNA IgG, VIRGO cANCA (PR-3) Kit, VIRGO dsDNA Kit, VIRGO ENA Screen 6 Kit, VIRGO ENA Screening, VIRGO ENA Series, VIRGO pANCA myeloperoxidase (MPO) Kit and VIRGO Rheumatoid Factor Kit. The company offers various products for infectious disease, which includes VIRGO C. trach IgG, VIRGO CMV IgG and VIRGO epstein-barr virus (EBV)- viral capsid antigen (VCA) IgG. Its products are used in laboratories, hospitals and blood banks around the world.
HMGN stock price ended at $0 on 金曜日, after dropping 100.00%
On the latest trading day Jan 23, 2026, the stock price of HMGN fell by 100.00%, dropping from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. On the latest trading day, the trading volume for HMGN rose by 500 shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 2.5K shares were traded, with a market value of approximately --.